We are analyzing https://link.springer.com/article/10.1007/s10549-011-1692-y.

Title:
Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells | Breast Cancer Research and Treatment
Description:
The majority of breast cancer deaths are because of ineffective treatment of metastatic disease. We previously identified a subpopulation of cells in human breast cancer cell lines that demonstrate high activity of aldehyde dehydrogenase (ALDH) and high expression of CD44. These ALDHhiCD44+ cells displayed enhanced metastatic behavior in vitro and in vivo relative to ALDHlowCD44− cells. The goal of this study was to test the hypothesis that ALDHhiCD44+ breast cancer cells are more resistant to standard cancer therapy, and that inhibiting ALDH activity through all-trans retinoic acid (ATRA) or the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) sensitizes these cells to treatment. ALDHhiCD44+ and ALDHlowCD44− populations were isolated from MDA-MB-231 and MDA-MB-468 cells lines and exposed to chemotherapy (doxorubicin/paclitaxel) or radiotherapy ± ATRA or DEAB. Cell populations were assessed for differences in survival, colony formation, and protein expression related to therapy resistance and differentiation. Significantly more ALDHhiCD44+ cells survived chemotherapy/radiotherapy relative to ALDHlowCD44− cells (P < 0.001). Glutathione-S-transferase pi, p-glycoprotein, and/or CHK1 were overexpressed in ALDHhiCD44+ populations compared with ALDHlowCD44− populations (P < 0.05). Pre-treatment of cell populations with DEAB or ATRA had no effect on ALDHlowCD44− cells, but resulted in significant initial sensitization of ALDHhiCD44+ cells to chemotherapy/radiotherapy. However, only DEAB had a long-term effect, resulting in reduced colony formation (P < 0.01). ATRA also significantly increased expression of CK8/18/19 in MDA-MB-468 ALDHhiCD44+ cells compared with control (P < 0.05). Our novel findings indicate that ALDHhiCD44+ breast cancer cells contribute to both chemotherapy and radiation resistance and suggest a much broader role for ALDH in treatment response than previously reported.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

cancer, google, scholar, article, pubmed, cells, cas, breast, cell, acid, stem, aldehyde, dehydrogenase, aldh, retinoic, resistance, human, res, chemotherapy, expression, aldhhicd, protein, research, allan, clin, treatment, alison, lines, london, radiation, croker, metastatic, therapy, alltrans, acute, promyelocytic, leukemia, privacy, cookies, content, stemlike, aldhlowcd, atra, deab, populations, access, gene, wicha, mol, doi,

Topics {✒️}

ccaat/enhancer-binding protein beta month download article/chapter glutathione-s-transferase pi mda-mb-468 cells lines pml-rar-alpha oncogene therapy-related myeloid neoplasms sh-sy5y neuroblastoma cells antagonizing p53-mediated apoptosis human aldehyde dehydrogenase regulates aldehyde dehydrogenase human aldehyde dehydrogenases breast cancer cells cd44-positive cells pancreatic cancer cells cancer stem cells glioma stem cells metastatic breast cancer full article pdf high aldehyde dehydrogenase breast cancer deaths inflammatory breast cancer advanced breast cancer lung cancer cells slug mediate radioresistance acute promyelocytic leukemia aldehyde dehydrogenase expression privacy choices/manage cookies ovarian cancer cells promote cell migration standard cancer therapy aldhhicd44+ populations compared breast cancer resistant activity reduces chemotherapy cd44 receptor interacts breast cancers protein expression related oxazaphosphorine-specific resistance epirubicin-based chemotherapy trans retinoic acid trans-retinoic acid bmc cancer 10 demonstrate high activity charafe-jauffret src inhibitor dasatinib n-cadherin chk1 estradiol-stimulated growth cancer statistics european economic area significant initial sensitization e-cadherin cdh2

Questions {❓}

Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB (2008) Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells
         description:The majority of breast cancer deaths are because of ineffective treatment of metastatic disease. We previously identified a subpopulation of cells in human breast cancer cell lines that demonstrate high activity of aldehyde dehydrogenase (ALDH) and high expression of CD44. These ALDHhiCD44+ cells displayed enhanced metastatic behavior in vitro and in vivo relative to ALDHlowCD44− cells. The goal of this study was to test the hypothesis that ALDHhiCD44+ breast cancer cells are more resistant to standard cancer therapy, and that inhibiting ALDH activity through all-trans retinoic acid (ATRA) or the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) sensitizes these cells to treatment. ALDHhiCD44+ and ALDHlowCD44− populations were isolated from MDA-MB-231 and MDA-MB-468 cells lines and exposed to chemotherapy (doxorubicin/paclitaxel) or radiotherapy ± ATRA or DEAB. Cell populations were assessed for differences in survival, colony formation, and protein expression related to therapy resistance and differentiation. Significantly more ALDHhiCD44+ cells survived chemotherapy/radiotherapy relative to ALDHlowCD44− cells (P < 0.001). Glutathione-S-transferase pi, p-glycoprotein, and/or CHK1 were overexpressed in ALDHhiCD44+ populations compared with ALDHlowCD44− populations (P < 0.05). Pre-treatment of cell populations with DEAB or ATRA had no effect on ALDHlowCD44− cells, but resulted in significant initial sensitization of ALDHhiCD44+ cells to chemotherapy/radiotherapy. However, only DEAB had a long-term effect, resulting in reduced colony formation (P < 0.01). ATRA also significantly increased expression of CK8/18/19 in MDA-MB-468 ALDHhiCD44+ cells compared with control (P < 0.05). Our novel findings indicate that ALDHhiCD44+ breast cancer cells contribute to both chemotherapy and radiation resistance and suggest a much broader role for ALDH in treatment response than previously reported.
         datePublished:2011-08-05T00:00:00Z
         dateModified:2011-08-05T00:00:00Z
         pageStart:75
         pageEnd:87
         sameAs:https://doi.org/10.1007/s10549-011-1692-y
         keywords:
            Breast cancer
            Stem-like cells
            Aldehyde dehydrogenase
            Therapy resistance
            All-trans retinoic acid
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig6_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:133
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alysha K. Croker
               affiliation:
                     name:University of Western Ontario
                     address:
                        name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
                        type:PostalAddress
                     type:Organization
                     name:London Regional Cancer Program
                     address:
                        name:London Regional Cancer Program, London, Canada
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Alison L. Allan
               affiliation:
                     name:University of Western Ontario
                     address:
                        name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
                        type:PostalAddress
                     type:Organization
                     name:London Regional Cancer Program
                     address:
                        name:London Regional Cancer Program, London, Canada
                        type:PostalAddress
                     type:Organization
                     name:University of Western Ontario
                     address:
                        name:Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
                        type:PostalAddress
                     type:Organization
                     name:London Health Sciences Centre, Lawson Health Research Institute
                     address:
                        name:London Health Sciences Centre, Lawson Health Research Institute, London, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells
      description:The majority of breast cancer deaths are because of ineffective treatment of metastatic disease. We previously identified a subpopulation of cells in human breast cancer cell lines that demonstrate high activity of aldehyde dehydrogenase (ALDH) and high expression of CD44. These ALDHhiCD44+ cells displayed enhanced metastatic behavior in vitro and in vivo relative to ALDHlowCD44− cells. The goal of this study was to test the hypothesis that ALDHhiCD44+ breast cancer cells are more resistant to standard cancer therapy, and that inhibiting ALDH activity through all-trans retinoic acid (ATRA) or the specific ALDH inhibitor diethylaminobenzaldehyde (DEAB) sensitizes these cells to treatment. ALDHhiCD44+ and ALDHlowCD44− populations were isolated from MDA-MB-231 and MDA-MB-468 cells lines and exposed to chemotherapy (doxorubicin/paclitaxel) or radiotherapy ± ATRA or DEAB. Cell populations were assessed for differences in survival, colony formation, and protein expression related to therapy resistance and differentiation. Significantly more ALDHhiCD44+ cells survived chemotherapy/radiotherapy relative to ALDHlowCD44− cells (P < 0.001). Glutathione-S-transferase pi, p-glycoprotein, and/or CHK1 were overexpressed in ALDHhiCD44+ populations compared with ALDHlowCD44− populations (P < 0.05). Pre-treatment of cell populations with DEAB or ATRA had no effect on ALDHlowCD44− cells, but resulted in significant initial sensitization of ALDHhiCD44+ cells to chemotherapy/radiotherapy. However, only DEAB had a long-term effect, resulting in reduced colony formation (P < 0.01). ATRA also significantly increased expression of CK8/18/19 in MDA-MB-468 ALDHhiCD44+ cells compared with control (P < 0.05). Our novel findings indicate that ALDHhiCD44+ breast cancer cells contribute to both chemotherapy and radiation resistance and suggest a much broader role for ALDH in treatment response than previously reported.
      datePublished:2011-08-05T00:00:00Z
      dateModified:2011-08-05T00:00:00Z
      pageStart:75
      pageEnd:87
      sameAs:https://doi.org/10.1007/s10549-011-1692-y
      keywords:
         Breast cancer
         Stem-like cells
         Aldehyde dehydrogenase
         Therapy resistance
         All-trans retinoic acid
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-011-1692-y/MediaObjects/10549_2011_1692_Fig6_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:133
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alysha K. Croker
            affiliation:
                  name:University of Western Ontario
                  address:
                     name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
                     type:PostalAddress
                  type:Organization
                  name:London Regional Cancer Program
                  address:
                     name:London Regional Cancer Program, London, Canada
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Alison L. Allan
            affiliation:
                  name:University of Western Ontario
                  address:
                     name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
                     type:PostalAddress
                  type:Organization
                  name:London Regional Cancer Program
                  address:
                     name:London Regional Cancer Program, London, Canada
                     type:PostalAddress
                  type:Organization
                  name:University of Western Ontario
                  address:
                     name:Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
                     type:PostalAddress
                  type:Organization
                  name:London Health Sciences Centre, Lawson Health Research Institute
                  address:
                     name:London Health Sciences Centre, Lawson Health Research Institute, London, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:133
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Western Ontario
      address:
         name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
         type:PostalAddress
      name:London Regional Cancer Program
      address:
         name:London Regional Cancer Program, London, Canada
         type:PostalAddress
      name:University of Western Ontario
      address:
         name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
         type:PostalAddress
      name:London Regional Cancer Program
      address:
         name:London Regional Cancer Program, London, Canada
         type:PostalAddress
      name:University of Western Ontario
      address:
         name:Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
         type:PostalAddress
      name:London Health Sciences Centre, Lawson Health Research Institute
      address:
         name:London Health Sciences Centre, Lawson Health Research Institute, London, Canada
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alysha K. Croker
      affiliation:
            name:University of Western Ontario
            address:
               name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
               type:PostalAddress
            type:Organization
            name:London Regional Cancer Program
            address:
               name:London Regional Cancer Program, London, Canada
               type:PostalAddress
            type:Organization
      name:Alison L. Allan
      affiliation:
            name:University of Western Ontario
            address:
               name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
               type:PostalAddress
            type:Organization
            name:London Regional Cancer Program
            address:
               name:London Regional Cancer Program, London, Canada
               type:PostalAddress
            type:Organization
            name:University of Western Ontario
            address:
               name:Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
               type:PostalAddress
            type:Organization
            name:London Health Sciences Centre, Lawson Health Research Institute
            address:
               name:London Health Sciences Centre, Lawson Health Research Institute, London, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
      name:London Regional Cancer Program, London, Canada
      name:Department of Anatomy and Cell Biology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
      name:London Regional Cancer Program, London, Canada
      name:Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada
      name:London Health Sciences Centre, Lawson Health Research Institute, London, Canada
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(179)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.27s.

LINK . SPRINGER . COM {}